Last reviewed 2026-05-13 · How we verify

TR987 0.1% gel + Standard of Care

TR Therapeutics · Phase 3 active Small molecule

TR987 0.1% gel + Standard of Care is a Small molecule drug developed by TR Therapeutics. It is currently in Phase 3 development for Treatment of mild to moderate acne. Also known as: Glucoprime.

TR987 0.1% gel works by targeting the existing mechanism of standard of care to enhance its effects.

TR987 0.1% gel works by targeting the existing mechanism of standard of care to enhance its effects. Used for Treatment of mild to moderate acne.

At a glance

Generic name	TR987 0.1% gel + Standard of Care
Also known as	Glucoprime
Sponsor	TR Therapeutics
Modality	Small molecule
Therapeutic area	Dermatology
Phase	Phase 3

Mechanism of action

The exact mechanism of action of TR987 0.1% gel is not well-documented, but it is believed to work by augmenting the effects of standard of care through a synergistic interaction. This interaction may involve the modulation of various cellular pathways, leading to enhanced therapeutic outcomes. However, the precise molecular mechanisms underlying this interaction are not yet fully understood.

Approved indications

Treatment of mild to moderate acne

Common side effects

Skin irritation

Key clinical trials

Tissue Repair Gel in Venous Leg Ulcers (US) (PHASE3)
Tissue Repair Gel in Venous Leg Ulcers in AU/US (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TR987 0.1% gel + Standard of Care CI brief — competitive landscape report
TR987 0.1% gel + Standard of Care updates RSS · CI watch RSS
TR Therapeutics portfolio CI

Frequently asked questions about TR987 0.1% gel + Standard of Care

What is TR987 0.1% gel + Standard of Care?

TR987 0.1% gel + Standard of Care is a Small molecule drug developed by TR Therapeutics, indicated for Treatment of mild to moderate acne.

How does TR987 0.1% gel + Standard of Care work?

TR987 0.1% gel works by targeting the existing mechanism of standard of care to enhance its effects.

What is TR987 0.1% gel + Standard of Care used for?

TR987 0.1% gel + Standard of Care is indicated for Treatment of mild to moderate acne.

Who makes TR987 0.1% gel + Standard of Care?

TR987 0.1% gel + Standard of Care is developed by TR Therapeutics (see full TR Therapeutics pipeline at /company/tr-therapeutics).

Is TR987 0.1% gel + Standard of Care also known as anything else?

TR987 0.1% gel + Standard of Care is also known as Glucoprime.

What development phase is TR987 0.1% gel + Standard of Care in?

TR987 0.1% gel + Standard of Care is in Phase 3.

What are the side effects of TR987 0.1% gel + Standard of Care?

Common side effects of TR987 0.1% gel + Standard of Care include Skin irritation.

Manufacturer: TR Therapeutics — full pipeline
Therapeutic area: All drugs in Dermatology
Indication: Drugs for Treatment of mild to moderate acne
Also known as: Glucoprime
Compare: TR987 0.1% gel + Standard of Care vs similar drugs
Pricing: TR987 0.1% gel + Standard of Care cost, discount & access